BioProcess Technology Consultants, Inc. Publishes Report on the State of Mammalian Cell Culture Biomanufacturing
Published: Dec 14, 2011
This report provides a comprehensive analysis of the supply and demand for mammalian cell culture, including geographic distribution of manufacturing capacity, the impact of facility utilization rates on overall capacity requirements, and the influence of disposables and single-use technologies on manufacturing facility design and costs. It covers current mammalian cell culture capacity utilization in the biopharmaceutical industry, forecasts supply of and demand for this capacity through 2016, and reveals important details about the biomanufacturing marketplace.
“With just ten companies controlling over seventy percent of the total worldwide mammalian cell culture manufacturing capacity, decision makers must understand the full biomanufacturing landscape to stay competitive,” said BioProcess Technology Consultants’ President and Principal Consultant, Howard L. Levine, Ph.D. “Our comprehensive analysis gives senior executives and program managers essential market insight into the critical considerations affecting biomanufacturing. Since the publication of BPTC’s original report in 2008, a number of trends have continued to develop and gain traction in the marketplace, including technological advances in manufacturing processes, increased acceptance of single-use or disposable technologies, continued emergence of biosimilars and follow-on biologic products, and continued consolidation in the pharmaceutical and biopharmaceutical industries.”
For more information or to order a copy of “The State of Mammalian Cell Culture Biomanufacturing,” go to http://www.bptc.com/reports.php, email email@example.com, or call 781-281-2702. The report is available in electronic-copy format only for $4,950.
About BioProcess Technology Consultants
Founded in 1994, BPTC is the recognized worldwide leader in biologics CMC consulting, providing a full range of technical, regulatory, and strategic assistance to biopharmaceutical and biotechnology companies in the development and commercialization of biopharmaceutical products. The company works with clients to find solutions to the challenges of producing biopharmaceutical supply from clone to commercial®. BPTC specializes in helping develop manufacturing processes and strategies and assists in developing product discovery and process development programs that enhance the overall value of client companies. BPTC also helps investors make informed decisions by providing technical and business evaluations of new products and technologies and product discovery, development, and commercialization plans of potential investments and existing portfolio companies. For more information about BPTC, visit http://www.bptc.com and follow the Company on Twitter at bptcGlobal or LinkedIn at http://www.linkedin.com/company/bioprocess-technology-consultants-inc.